These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 17043732)
1. Lithium as an adjunct to radioiodine therapy in Graves' disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not? Dunkelmann S; Künstner H; Nabavi E; Eberlein U; Groth P; Schümichen C Nuklearmedizin; 2006; 45(5):213-8; quiz N51-2. PubMed ID: 17043732 [TBL] [Abstract][Full Text] [Related]
2. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves' disease. Dunkelmann S; Kuenstner H; Nabavi E; Rohde B; Groth P; Schuemichen C Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):228-36. PubMed ID: 17021811 [TBL] [Abstract][Full Text] [Related]
3. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents]. Urbannek V; Voth E; Moka D; Schicha H Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200 [TBL] [Abstract][Full Text] [Related]
4. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353 [TBL] [Abstract][Full Text] [Related]
5. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit? Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318 [TBL] [Abstract][Full Text] [Related]
6. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry? Eschner W; Kobe C; Schicha H Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262 [TBL] [Abstract][Full Text] [Related]
7. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure]. Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161 [TBL] [Abstract][Full Text] [Related]
8. The effect of short-term treatment with lithium carbonate on the outcome of radioiodine therapy in patients with long-lasting Graves' hyperthyroidism. Sekulić V; Rajić M; Vlajković M; Ilić S; Stević M; Kojić M Ann Nucl Med; 2017 Dec; 31(10):744-751. PubMed ID: 28895066 [TBL] [Abstract][Full Text] [Related]
9. [F-qi-FDG PET of the thyroid gland in Graves' disease]. Börner AR; Voth E; Wienhard K; Wagner R; Schicha H Nuklearmedizin; 1998; 37(7):227-33. PubMed ID: 9830612 [TBL] [Abstract][Full Text] [Related]
10. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement]. Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826 [TBL] [Abstract][Full Text] [Related]
11. [Two-step radioiodine therapy in benign thyroid diseases during a single hospital visit--observations on 100 patients]. Khandani A; Schicha H Nuklearmedizin; 1999; 38(5):140-3. PubMed ID: 10488480 [TBL] [Abstract][Full Text] [Related]
12. Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements. Liu B; Tian R; Peng W; He Y; Huang R; Kuang A J Clin Endocrinol Metab; 2015 Aug; 100(8):2934-41. PubMed ID: 26046966 [TBL] [Abstract][Full Text] [Related]
13. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554 [TBL] [Abstract][Full Text] [Related]
14. The feasibility of low-dose oral lithium therapy and its effect on thyroidal radioiodine uptake, retention, and hormonal parameters in various subcategories of hyperthyroid patients: a pilot study. Chouhan A; Abhyankar A; Basu S Nucl Med Commun; 2016 Jan; 37(1):74-8. PubMed ID: 26465804 [TBL] [Abstract][Full Text] [Related]
16. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease]. Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227 [TBL] [Abstract][Full Text] [Related]
17. [Concept and validation of a simple model of the intrathyroidal iodine kinetics]. Rink T; Bormuth FJ; Braun S; Zimny M; Schroth HJ Nuklearmedizin; 2004 Feb; 43(1):21-5. PubMed ID: 14978537 [TBL] [Abstract][Full Text] [Related]
18. [The importance of the radioiodine test for the calculation of the therapeutic dose in benign thyroid diseases]. Nüchel C; Boddenberg B; Schicha H Nuklearmedizin; 1993 Apr; 32(2):91-8. PubMed ID: 8479936 [TBL] [Abstract][Full Text] [Related]
19. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease]. Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674 [TBL] [Abstract][Full Text] [Related]
20. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents]. Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]